Product
Envarsus
5 clinical trials
12 indications
Indication
NeurotoxicityIndication
Liver TransplantIndication
Chronic Kidney DiseaseIndication
Adverse Reaction to ImmunosuppressantsIndication
Metabolic SyndromeIndication
Cardiovascular DiseasesIndication
Kidney TransplantIndication
ToxicityIndication
Drug ToxicityIndication
Liver Transplant RejectionIndication
Immune System SuppressionIndication
Kidney Transplant Failure and RejectionClinical trial
The Effect of Conversion to Once-Daily Envarsus® on the Neurologic Toxicity Burden in Liver Transplant RecipientsStatus: Completed, Estimated PCD: 2023-04-30
Clinical trial
Feasibility, Efficacy And Safety Of De Novo Extended-Release Tacrolimus Following Liver TransplantationStatus: Recruiting, Estimated PCD: 2025-07-15
Clinical trial
A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) PatientsStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Prograf/Envarsus Conversion Study in Liver Transplant Recipients to Improve Side Effects, Adherence and Quality of Life: A Single-centre Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant RecipientsStatus: Recruiting, Estimated PCD: 2023-12-01